Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

    Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

    Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

      Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

      Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

        Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1

        Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.

          Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

          Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

            Allergan (AGN) Beats on Q2 Earnings and Sales, Stock Up

            Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics.

              Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

              Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

                Allergan's Depression Candidate Gets Fast Track Designation

                The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.

                  Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

                  While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

                    AGN or TLGT: Which Is the Better Value Stock Right Now?

                    AGN vs. TLGT: Which Stock Is the Better Value Option?

                      AGN vs. TLGT: Which Stock Should Value Investors Buy Now?

                      AGN vs. TLGT: Which Stock Is the Better Value Option?

                        Ironwood Begins New Phase III Study to Expand Linzess Label

                        Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

                          Novartis Looks to Exit Antibacterial, Antiviral Program

                          Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

                            Mark Vickery headshot

                            Top Analyst Reports for Union Pacific, 21st Century Fox & BP

                            Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), Twenty-First Century Fox (FOXA) and BP plc (BP).

                              Adamis (ADMP) Surges Following Novartis Deal for Symjepi

                              Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.

                                The Zacks Analyst Blog Highlights: Bank of America, Wells Fargo, Honeywell, Allergan and Enterprise Products

                                The Zacks Analyst Blog Highlights: Bank of America, Wells Fargo, Honeywell, Allergan and Enterprise Products

                                  AGN vs. AMPH: Which Stock Is the Better Value Option?

                                  AGN vs. AMPH: Which Stock Is the Better Value Option?

                                    Has Allergan plc (AGN) Outpaced Other Medical Stocks This Year?

                                    Is (AGN) Outperforming Other Medical Stocks This Year?

                                      Is Allergan (AGN) a Suitable Stock for Value Investors Now?

                                      Let's see if Allergan plc (AGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                        Mark Vickery headshot

                                        Top Research Reports for Bank of America, Wells Fargo & Honeywell

                                        Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Wells Fargo (WFC) and Honeywell (HON).

                                          Paratek's Antibiotic Candidate Gets FDA Committee Date

                                          Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.

                                            Allergan (AGN) Presents Positive Data on Glaucoma Candidate

                                            Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

                                              Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

                                              Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

                                                Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe

                                                Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.

                                                  Allergan Requests Shareholders to Veto Management Change

                                                  Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.